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Abstract. Camptothecin is an S-phase-specific antican- 
cer agent that inhibits the activity of the enzyme DNA 
topoisomerase-I (topo-I). Irreversible DNA double- 
strand breaks are produced during DNA synthesis in 
the presence of camptothecin, suggesting that this agent 
should not be toxic to nondividing cells, such as neu- 
rons. Unexpectedly, camptothecin induced significant, 
dose-dependent cell death of postmitotic rat cortical 
neurons in vitro; astrocytes were more resistant. Aphid- 
icolin, an inhibitor of DNA polymerase a, did not pre- 
vent camptothecin-induced neuronal death, while 
death was prevented by actinomycin D and 5,6- 
dichloro-l-beta-o-ribofuranosyl benzimidazole as well 
as cycloheximide and anisomycin, inhibitors of RNA 
and protein synthesis, respectively. Camptothecin- 
induced neuronal death was apoptotic, as characterized 
by chromatin condensation, cytoplasmic shrinking, 
plasma membrane blebbing, and fragmentation of neu- 
rites, DNA fragmentation was also confirmed by the 
use of the in situ DNA end labeling assay. In addition, 
aurintricarboxylic acid, an inhibitor of the apoptotic en- 
donuclease, partially protected against camptothecin- 
induced neuronal death. The toxicity of stereoisomers 
of a camptothecin analogue was stereospecific, demon- 
strating that toxicity was a result of inhibition of topo-I. 
The difference in sensitivity to camptothecin between 
neurons and astrocytes correlated with their transcrip- 
tional activity and level of topo-I protein expression. 
These data indicate important roles for topo-I in post- 
mitotic neurons and suggest that topo-I inhibitors can 
induce apoptosis independent of DNA synthesis. We 
suggest a model based on transcriptionally mediated 
DNA damage, a novel mechanism of action of topo-I 
poisons. 
p 
ROGRAMMED cell death is an important physiological 
process  that results in the  death of ~50%  of the 
neurons  formed during  embryogenesis (46).  This 
death is normally thought to result from neuronal compe- 
tition for trophic support; thus, neurons that do not find 
their correct targets are eliminated. Neuronal programmed 
cell death occurs by the process of apoptosis, characterized 
by chromatin condensation, endonucleolytic DNA cleav- 
age,  cytoplasmic shrinkage, plasma  membrane  blebbing 
and contraction (a term also called zeiosis [10]), fragmen- 
tation of neurites, and formation of apoptotic bodies (30). 
Apoptosis is an "active" cellular process in which the cell 
"commits suicide" and is distinct from necrosis, which is 
characterized by lysis or disintegration of the cell, a "pas- 
sive" form of cell death. 
Much of our understanding of the biochemical and mo- 
lecular  events  associated  with  neuronal  apoptosis  has 
come from the study of cultured central  and peripheral 
neurons as well as work from cell lines which exhibit neu- 
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ronal properties. The typical paradigm for apoptotic neu- 
ronal death uses trophic factor-dependent cells in which 
trophic  support  is  withdrawn  and  the  subsequent  cell 
death is  studied. In particular, the study of sympathetic 
neurons, whose survival is dependent upon NGF in vitro 
and in vivo, has contributed a significant amount of infor- 
mation regarding the biochemical profile of apoptotic neu- 
ronal death (15).  One key characteristic of this profile is 
that after NGF withdrawal neurons begin to die by apop- 
tosis and this cell death can be prevented with inhibitors of 
RNA and protein synthesis (37).  These data suggest that 
after NGF deprivation, an active genetic program is initi- 
ated which results in subsequent  neuronal death. These 
data also suggest that trophic factors act by repressing an 
endogenous death pathway as  opposed  to  stimulating a 
cell survival pathway. Currently, however, the biochemical 
and genetic events involved in the apoptotic pathway in 
neurons remain poorly understood. 
Although  apoptotic  cell  death  occurs  physiologically 
during development, neuronal apoptosis is also associated 
with a variety of neurodegenerative disorders and condi- 
tions of neural trauma including Alzheimer's disease, Par- 
kinson's disease, Huntington's disease, amyotrophic lateral 
sclerosis, AIDS dementia, epilepsy, retinitis pigmentosa, 
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stroke  (57).  This  suggests  that  the  biochemical  mecha- 
nisms  of physiological and  pathological neuronal death 
may overlap. Moreover, a variety of metabolic insults can 
induce apoptotic death of neuronal cells (14, 51, 56), sug- 
gesting that the trophic factor-mediated repression of the 
death pathway can either be inhibited or overridden by 
other stimuli. Of particular interest is the induction of apop- 
tosis in postmitotic neurons by antimitotic anticancer agents. 
Treatment of both rat sympathetic and cerebellar neurons 
with the  S-phase-specific inhibitor, cytosine arabinoside 
(AraC) 1, results in apoptosis in vitro (15, 18). In addition, 
some patients treated with high-dose AraC therapy for re- 
fractory leukemia develop a cerebellar toxicity syndrome 
characterized by the death of nondividing Purkinje neu- 
rons (63, 67). Adenosine arabinoside can also induce apop- 
tosis in rat sympathetic neurons, although with lesser po- 
tency as compared with AraC (59). Similarly, treatment of 
sympathetic or cerebral cortical neurons with the G2/M- 
phase-specific DNA  topoisomerase-II inhibitors,  etopo- 
side, teniposide, or mitoxantrone, also results in apoptotic 
death (42, 43, 59). Currently, it is unknown how these anti- 
cancer agents signal a  terminally differentiated, postmi- 
totic neuron to execute its apoptotic pathway or how a va- 
riety of stimuli activate a morphologically indistinguishable 
death response. 
Camptothecin is a cytotoxic plant alkaloid originally iso- 
lated from the Chinese Camptotheca acuminata tree (64). 
This compound and its analogues are S-phase, cell cycle- 
specific, anticancer agents that inhibit the activity of mam- 
malian DNA topoisomerase-I (topo-I) (for review see 7). 
The major function of topo-I is to relax DNA supercoiling 
produced by the torsional stress generated during DNA 
replication and transcription (for review see 65).  During 
this process, camptothecin binds to the topo-I/DNA com- 
plex  (termed the cleavable-complex [27]),  resulting in  a 
DNA single-strand break. Attempts by the cell to enter 
S-phase of the cell cycle, in the presence of camptothecin, 
result in late S- and early G2-phase arrest with the con- 
comitant conversion of DNA single-strand breaks into po- 
tentially lethal,  irreversible  DNA  double-strand  breaks 
(27). This ultimately results in cell death via the apoptotic 
pathway (17).  It is hypothesized that toxicity arising from 
camptothecin treatment results  from the  actions  of the 
replicative  machinery colliding with  the  cleavable-com- 
plex, resulting in DNA double-strand breaks:  hence, its 
S-phase specificity (28). 
Due to its cell cycle specificity, camptothecin would be 
expected to be relatively nontoxic to differentiated, post- 
mitotic cells, such as neurons, at concentrations known to 
inhibit topo-I function. In this study, we have tested this 
hypothesis by investigating the effects of camptothecin on 
postmitotic cells derived from the nervous system. Unex- 
pectedly, camptothecin induced an apoptotic cell death in 
postmitotic cortical neurons that was apparently mediated 
by the target enzyme, topo-I. Aphidicolin cotreatment did 
not  prevent  camptothecin-induced neuronal  death,  sug- 
1.  Abbreviations used  in  this paper:  AraC, cytosine arabinoside; BrdU, 
bromodeoxyuridine; CF, carboxyfluorescein; CFDA, 5(6)-carboxyfiuores- 
cein diacetate; DAPI, 4',6-diamidino-2-phenylindole;  TdT, terminal deoxy- 
ribonucleotidyl transferase; topo-I, DNA topoisomerase-I. 
gesting that replication does not contribute to camptothe- 
cin  neurotoxicity.  However,  camptothecin-induced  cell 
death was inhibited by RNA and protein synthesis inhibi- 
tors,  suggesting that active transcription and  translation 
was necessary for toxicity. These data demonstrate that 
topo-I function is important for neuronal survival and that 
inhibition of this enzyme results in apoptosis. Moreover, 
since camptothecin-induced cell death of nondividing cells 
must  be  independent  of  DNA  replication,  alternative 
mechanisms of camptothecin-induced cell death must ex- 
ist. We suggest that non-S-phase toxicity of camptothecin 
is  dependent  upon  active  DNA  transcription,  a  novel 
mechanism of action of topo-I poisons. 
Materials and Methods 
Materials 
Timed-pregnant Sprague-Dawley rats were obtained from Hilltop Lab 
Animals, Inc.  (Scottsdale, PA). FCS  and Basal Media Eagle's (BME) 
were obtained from Sigma Chemical Co. (St. Louis, MO). DME was ob- 
tained from Gibco BRL (Grand Island, NY). Nylon mesh for filtering cul- 
tured cells was purchased from Tetko (Elmsford, NY), 20-S-eamptothecin 
(referred to in the text as camptothecin) and 20-S- and 20-R- 10-11-meth- 
ylenedioxycamptothecin (MDCPT) were obtained as gifts from the labo- 
ratory  of Dr.  Leroy F.  Liu  (UMDNJ-Robert  Wood Johnson Medical 
School). [5-3H]uridine  was obtained from Amersham Life Sciences (Buck- 
inghamshire, England).  [4,5-3H]L-leucine  was  obtained from ICN  Bio- 
medicals (Irvine, CA). All other reagents and tissue culture supplies were 
obtained from Sigma Chemical Co. 
Cell Cultures 
Astrocyte cultures were prepared by the method previously described 
(39). Cerebral cortices were removed from newborn rats (postnatal d 1-3) 
and placed into cold BME media with 0.02 M Na-Hepes buffer, pH 7.4 
(BME-Hepes). The meningeal tissue and white matter was removed and 
the remaining tissue was minced into fine sections (1 ram) with sharp dis- 
secting knives. The minced sections were incubated with 0.025% trypsin 
(type-II) for 30 min at 37°C. The reaction was halted with 0.025%  soybean 
trypsin inhibitor and 0.05% DNAse-I and the tissue was triturated several 
times through a fire-polished Pasteur pipette. The suspension was passed 
through sterile 40-i.Lm nylon mesh cloth to remove large cell aggregates 
and then centrifuged for 5 min at 1,000 g. The pellet was resuspended in 
medium composed of DME supplemented with 10% heat-inactivated FCS, 
NaHCO3 (2.2 mg/ml), penicillin (50 ~g/ml), and streptomycin (50 U/ml) 
(DME/10%  FCS). The cells were plated into poly-L-lysine--coated (100 
tJ,  g/ml) 80-cm  2 culture flasks (Nunc) and incubated at 37~C in 95%:5% air/ 
CO2  atmosphere with 100%  relative humidity. When the cells become 
confluent (~10 d), the flasks were shaken overnight (185 rpm) on a rotary 
shaker to remove loosely adherent cells (neurons, O-2A progenitors, mac- 
rophages, and oligodendrocytes). Astrocytes are routinely screened via 
immunofluorescence techniques for the expression of GFAP as well as for 
the absence of oligodendrocyte and neuronal markers, and this culture 
method generally yields >95% GFAP-positive cells. For astrocyte mono- 
layers, cells were plated at 3--4 x  104 cells per well in poly-L-lysine--coated 
24-well plates (Falcon Plastics) in 0.5 ml of DME/10% FCS and allowed to 
become confluent (confluency equals approximately 7  x  104 astrocytes 
per 24 well). After the cells reached confluency, they were incubated with 
DME/2% FCS and the media was changed approximately every 3 d. 
Primary dissociated cortical neurons were prepared by the method pre- 
viously described (62). Briefly, timed-pregnant Sprague-Dawley rats were 
killed at embryonic day 17 (El7)  and embryos were removed by Cae- 
sarian section. The cerebral cortex was dissected from each embryonic 
brain, the meningeal tissue was carefully removed, and the cortex was 
finely minced into sections (<0.5 mm) with sharp dissecting knives. The 
sections were placed into cold BME-Hepes and incubated with 0.025% 
trypsin (type-II) and 0.1% type-IV collagenase for 30 min at 37°C. The re- 
action  was  halted  with  0.025%  soybean  trypsin  inhibitor  and  0.05% 
DNAse-I and the tissue was gently triturated several times through a fire- 
polished Pasteur pipette. The cells were filtered through sterile 40-1~m 
mesh, resuspended in DME/10% FCS, and plated at a density of 1.5 ×  105 
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maintained in DME/2% FCS. The astrocyte monolayer provides optimal 
trophic support for embryonic cortical neuronal survival (62). After ,'-5-6 d 
in vitro, the mixed cultures were treated as indicated below. To ensure 
that neurons were postmitotic, after 5 d in vitro cultures were incubated 
with 10 wM bromodeoxyuridine (BrdU) for 24 h. BrdU incorporation into 
DNA was evaluated immunocytochemically. Less than 0.1% of the neu- 
rons incorporated BrdU, demonstrating that 99.9% of these cells were ter- 
minally differentiated and postmitotic. Approximately 5%  of the astro- 
cytes displayed BrdU immunoreactivity, suggesting  that they maintained a 
low degree of proliferation. 
Treatment of Cultures with Pharmacological  lnhibitors 
Cells were treated for the experiments below as indicated. Neurons and 
astrocytes were incubated with pharmacological inhibitors in serum-free 
N2 medium or DME/2%  FCS. The presence of serum had no effect on 
neuron or astrocyte survival after treatment with camptothecin (data not 
shown). Survival after treatment with the pharmacological inhibitors was 
compared  with  parallel  treatment  with  control  medium.  Aphidicolin, 
DRB, camptothecin, and MDCPT stock solutions were dissolved in 100% 
DMSO. Control cultures were incubated with <0.5% DMSO solutions as 
vehicle control. Solutions of <0.5% DMSO were not toxic to neurons or 
astrocytes within the time range of the experiments described below. 
CFDA Assay for Neuronal Survival 
Neuronal survival was determined using an assay based upon the vital dye 
5(6)-carboxyfluorescein diacetate  (CFDA)  (49).  Mixed neuronal-astro- 
cyte  cultures  were  washed  once  with  Hepes-buffered  saline  solution 
(HBS; 122 mM NaC1, 3.3 mM KC1,  1.2 mM CaCl  2, 0.4 mM MgSO4, 1.2 
mM KH2PO4, 10 mM glucose, 25 mM Hepes at pH 7.3) and incubated 
with 10 p,M CFDA in HBS for 15 min at 37°C in 95%:5% air/CO2 atmo- 
sphere with 100%  relative humidity, protected  from light. Under these 
conditions, both astrocytes and neurons take up and cleave CFDA to the 
anionic fluorophore, carboxyfluorescein (CF), by the activity of endoge- 
nous cellular esterases. The media were then aspirated and the cells were 
incubated with HBS for 30 min as a rinse, during which astrocytes pump 
CF into the media, while neurons retain it for hours. The rinse was aspi- 
rated and cells were lysed with water containing 0.1% Triton X-100. The 
lysate was then diluted 1:10 in 0.1 M PBS and the fluorescence measured 
using a  Perkin-Elmer MPF-66 fluorescence spectrofluorometer (excita- 
tion k 490 nm, emission ~ 517 nm). Fluorescence intensity is linearly pro- 
portional to the number of metabolically viable neurons (49). Under con- 
trol conditions, relative fluorescence for 1.5 x  105 neurons per 24 well was 
~2,000 arbitrary units, while background fluorescence (identical cultures 
without neurons) was ~10 U. Therefore, ,'-'99.5%  of the CF fluorescence 
is  contributed  by  neurons.  To  ensure  accurate  fluorometric  measure- 
ments, each experiment was performed in parallel with a standard CF cal- 
ibration curve. 
For neuronal CF labeling, mixed cultures of neurons and astrocytes 
were grown on glass coverslips in 24-well plates, incubated with 10 rtM 
CFDA in HBS for 15 min, and rinsed as described above. After rinsing, 
the coverslips were inverted and mounted within a ring of vacuum grease 
on a glass slide in a drop of HBS. The coverslip was viewed under fluores- 
cein epifluorescence and images captured as previously described (49). 
MTI" Viability Assay 
Astrocyte survival was assayed by the colorimetric conversion of the yel- 
low,  water-soluble  tetrazolium,  MTT  (3-[4,5-dimethylthiazol-2-yl]-2,5- 
diphenyltetrazolium bromide) to the purple, water-insoluble formazan. 
This conversion is catalyzed  by cellular mitochondrial dehydrogenases 
and therefore, can be utilized to quantify numbers of viable cells (40). 
Cells were assayed by a modified protocol of the procedure previously de- 
scribed (1). Ceils were incubated with 0.1 mg/ml MTT solution in DME 
without phenol red for 4 h  at 37°C in 95%:5%  air/CO2 atmosphere with 
100%  relative humidity. After the incubation, the cells were  triturated 
into suspension and centrifuged at 8,000 g for 5 min at 4°C. The superna- 
tant was discarded and the pellet was resuspended in 0.g N  HCl-isopro- 
panol solution (pH 3) containing 1% Triton X-100, which lyses the cells 
and solubilizes the formazan product. The absorbance of the lysate was 
measured at  570  nm with  a  microplate  reader  (Bio-Tek  Instruments). 
Neurons  and  astrocytes totally  converted  the  MTr  formazan product 
within ~3~  h. Calibration curves were conducted in parallel experiments 
which demonstrated a  linear correlation between MTI" absorbance and 
cell number. 
lmmunohistochemistry 
Cells were fixed with ice-cold ethanol/acetic acid (95:5)  for 8 min at 4°C 
and rinsed three times in 0.1 M PBS containing 0.1% sodium azide (PBS- 
azide) and once in PBS-azide with 10% FCS as a blocking agent. To label 
neurons, coverslips were incubated with a 1:100 dilution of mouse mono- 
clonal anti-neurofilament RT97 antibody (the generous gift of Dr. John 
Wood, University College, London, UK) for 30 min at 4°C. After rinsing, 
the  coverslips  were  incubated  with  rhodamine-conjugated  goat  anti- 
mouse IgG secondary antibody (Organon-Technika Cappel) for 30 min at 
4°C (1:100  dilution). For nuclear staining, cells were fixed and then incu- 
bated with 1  p,g/ml 4',6-diamidino-2-phenylindole (DAPI)  for 5  min at 
room temperature. After rinsing, the coverslips were mounted in Fluoro- 
mount G  (Southern Biotechnology Associates, Inc.) and sealed with nail 
enamel. 
Identification of  DNA Topoisomerase-I 
Protein Expression 
DNA topoisomerase-I protein levels were measured using immunoblot- 
ring techniques. Samples consisted of cellular extracts prepared from (a) E 
17 rat cerebral cortex, (b) neurons cultured 2 d in vitro from E 17 rat cere- 
bral cortex (with addition of 1 ~M 5-fluorodeoxyuridine and 1 p,M uridine 
at 1 d in vitro to kill dividing cells), and (c) confluent cultures of purified 
astrocytes cultured from newborn rat cerebral cortex.  Cellular extracts 
were prepared by lysing cells in homogenization buffer consisting of 1% 
SDS, 8%  sucrose, 2 mM EDTA, 3 mM EGTA, and 50 mM phosphate 
buffer (pH 8.0).  Protein concentrations were determined using the Bio- 
Rad-DC protein assay. Laemmli sample buffer (5x) was added to the ex- 
tracts and the samples were heated to 100°C for 5 min. Cell extracts (20 
p.g/lane) were subjected to 10% SDS-PAGE (33) and then transferred to 
nitrocellulose paper  (40  mA, 15  h)  (60).  The blots were  incubated  in 
blocking solution containing 5% dry milk (Carnation® brand) in TBS (20 
mM Tris-HCI, pH 7.5, 0.5 M NaCI) for 1 h and then incubated for 2 h in a 
solution of primary antibody (rabbit anti-human DNA topoisomerase-I) 
diluted 1:1,000  in 3%  dry milkfrBS. The blots were then washed three 
times (15 min per wash) in TBS containing 0.05%  Tween 20 and incu- 
bated with alkaline phosphatase-conjugated goat anti-rabbit IgG (Sigma 
Chemical Co.) at a  I:1,000 dilution. The blots were washed again three 
times as above and DNA topoisomerase-I protein was detected colorimet- 
rically using 5-bromo-4-chloro-3-indolyl-phosphate and nitroblue tetrazo- 
lium development. All antibody incubations and washes were  done  at 
room temperature. Each immunoblot was run with 10 v,L/lane of kaleido- 
scope prestained standards (BioRad) mol wt markers. Relative levels of 
protein expression were determined by analyzing the pixel intensity of the 
bands using the NIH-Image program (version 1.59).  In addition, parallel 
SDS-PAGE gels were stained with Coomassie brilliant blue to ensure ad- 
equate protein loading of the gels. Immunoreactivity was not detected in 
the negative control blots in which the primary antibody was omitted. 
Analysis of  DNA Fragmentation 
Mixed cultures were analyzed for apoptotic DNA fragmentation by the 
terminal deoxyribonucleotidyl transferase-mediated dUTP-biotin in situ 
nick end labeling (TUNEL) assay using the ApopTag® kit (Oncor, Gaith- 
ersburg, MD). This assay uses the ability to label free 3'-OH DNA ends 
that are generated by nuclear endonucleolytic cleavage of DNA which oc- 
curs during apoptosis (24). The free 3'-OH DNA ends are labeled with 
digoxigenin-dUTP  via  the  terminal  deoxyribonucleotidyl  transferase 
(TdT) enzyme. The kit was used according to the manufacturers instruc- 
tions except that it was modified for cultured cells growing on 12-mm glass 
coverslips. Neurons were plated at a density of 5 x  104 cell/well on preex- 
isting astrocyte monolayers grown on poly-L-lysine-coated (100 wg/ml) 
12-mm glass coverslips in 24-well trays (Falcon). The cells were fixed with 
ice-cold ethanol/acetic acid (95:5) for 8 min at 4°C and rinsed three times 
in 0.1 M  PBS. The coverslips were quenched with 30 wl/coverslip of 2% 
H202 in PBS for 5 min at room temperature, rinsed three times in PBS, 
and incubated with 15 ~l/coverslip of 1 X equilibration buffer for 20 min 
at room temperature. The cells were then incubated with 10 V.1/cm  z (15 I*1/ 
coverslip) of working strength TdT enzyme (1:2.4 TdT enzyme/reaction 
buffer) at 37°C in 95 %:5% air/CO2 atmosphere with 100% relative humid- 
ity. The reaction was stopped by rinsing three times in PBS and adding 15 
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The cells were rinsed and incubated with 25 i~L/coverslip of peroxidase 
conjugated anti-digoxigenin secondary antibody for 30 min in the incuba- 
tor. The cells were then rinsed and color developed using a 0.75% diami- 
nobenzidine tetrahydrochloride solution and mounted on glass slides. As 
a positive control, cells were incubated with 1 ixg/ml of DNAse-I solution, 
containing 1 mM MgSO4 and 10.2 mM Na-Hepes at pH 7.4, before incu- 
bation with TdT enzyme. As a negative control, water was substituted in- 
stead of TdT enzyme. 
Determination of RNA and Protein Synthesis 
For determination of RNA synthesis rates, mixed cultures of neurons and 
confluent astrocytes as well as purified cultures of confluent astrocytes 
were  prepared  and  plated  in  24-well  tissue culture  trays  as  described 
above. Cells were washed once with 0.1 M PBS and pulse labeled with 0.5 
ml/weU of media (DME/2%  FCS) plus 1 i~Ci/ml of [5-3H]uridine (27 Ci/ 
mmol) and 20 ~M uridine for various time points up to 4 h, in a shaking 
metabolic incubator perfused with 5% COz:95% air at 37°C. After the in- 
cubation period, the media was aspirated and the cells were washed twice 
with cold PBS. The cells were then lysed with cold 10% TCA and centri- 
fuged at 12,000 g for 15 min at 4°C. Aliquots of the supernatant were used 
for determination of the amount of free intracellular, radiolabeled uridine 
using a  liquid scintillation counter. The pellet was solubilized with 1 M 
hyamine hydroxide (ICN Biochemicals) and aliquots used for determina- 
tion  of the amount of incorporated,  acid-precipitable,  radiolabeled  uri- 
dine. RNA synthesis  rates for neurons were determined by subtracting the 
amount of incorporation of [3H]uridine by astrocytes from that of mixed 
cultures and normalizing to cellular protein. To determine the effects of 
camptothecin, DRB and ActD on RNA synthesis, cells were incubated 
with the inhibitors for 5  h  as described above and the acid-precipitable 
counts under experimental conditions were divided by acid-precipitable 
counts under control conditions and normalized to protein levels as de- 
scribed  previously  (9).  Protein  synthesis was  similarly  determined  in 
mixed cultures of neurons and astrocytes and confluent astrocyte cultures. 
Cells were  incubated in leucine-deflcient media and pulse labeled with 
1 ixCi/ml of [4,5-3H]L-leucine (77 Ci/mmol) and 20 IxM L-leucine for 5 h in 
the presence or absence of increasing concentrations of CHX. Protein syn- 
thesis for neurons was determined by subtracting the amount of incorpo- 
rated, acid-precipitable [3H]leucine by astrocytes from that of mixed cul- 
tures and normalizing to cellular protein. 
Electronic Imaging 
Bright-field phase, differential interference contrast, and fluorescence im- 
ages were captured using a Dage CCD72 camera and Dage DSP2000 digi- 
tal  signal processor (capable  of on-chip integration for  low-light situa- 
tions), and a  Macintosh Quadra 700 with a  Scion LG-3 frame grabber 
board. Images were analyzed with the NIH Image program (V 1.57, avail- 
able by anonymous FTP from zippy.nimh.nih.gov) and further processed 
with  Adobe  Photoshop  software.  Final  prints  were  produced  using a 
Kodak 7700 color printer. 
Time Lapse Videomicroscopy 
Cortical neurons (5.6 ×  104 cells/cm  2) were grown for 6-7 d in vitro on a 
preexisting monolayer of astrocytes in PLL-coated  (100  }xg/ml) 10  cm  2 
Nunc chamber flasks. At the beginning of the observation period, cells 
were washed twice with PBS and incubated with DME/2%  FCS with or 
without camptothecin. The flasks were sealed and placed on the stage of a 
Figure 1.  Camptothecin-induced cell death in mixed cultures of neurons and astrocytes. (A) Phase-contrast image of a control culture of 
dissociated embryonic rat cerebral cortical neurons at 6  d  in vitro.  (B) Phase-contrast image of culture after 24 h  of treatment with 10 
p~M camptothecin. (C) Control culture labeled with CF demonstrating brightly stained neuronal somata and meshwork of neuritic pro- 
cesses. (D)  Image of a  culture treated with 10 IxM camptothecin for 24 h  and labeled with CF demonstrating fewer surviving neurons 
and extensive fragmentation of neurites. Bar, 50 ~m. 
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kon NP2 thermostatic heater. Cultures were observed using a 40× phase 
contrast objective and images were recorded with an RCA TC-1005 cam- 
era and RCA TC-3700 time lapse video recorder at a time reduction of 2 
rain to 1 s (1:120). Selected frames were captured during video playback 
by the NIH Image Program using a Data Translation DT2255 frame grab- 
ber card. 
Results 
Camptothecin Induces Neuronal Cell Death 
Camptothecin  (10  IxM)  was  added  to mixed  cultures  of 
neurons  and  astrocytes  as  described  in  Materials  and 
Methods, and survival was evaluated at 24 h. At this time, 
control cultures consisted of healthy, phase-bright neurons 
on top of the flat astrocyte monolayer (Fig. 1 A). In con- 
trast, cultures treated with camptothecin contained fewer 
surviving neurons and showed accumulation of cell debris 
on the astrocyte monolayer (Fig. 1 B). Moreover, surviv- 
ing neurons demonstrated  neurite  fragmentation  and so- 
mal  blebbing.  In  contrast,  the  astrocyte  monolayer  re- 
mained  healthy  and  intact,  with  no  apparent  changes in 
astrocyte morphology. Incubation with CFDA provided a 
clearer  demonstration  of these morphological changes in 
neurons.  In  control  cultures,  neurons  appeared  healthy 
with an elaborate mesh of neurites and brightly stained so- 
mata  (Fig.  1  C).  In camptothecin-treated  cultures,  there 
was a reduction in CF fluorescence, due to both a decrease 
in the number of surviving neurons as well as a loss of neu- 
rites (Fig. 1 D). In addition, camptothecin-treated cultures 
contained  a  large  amount of CF-stained  debris,  which is 
likely due to the hydrolysis of CFDA by neuronal  apop- 
totic bodies• 
We then determined the dose and time dependence  of 
camptothecin-induced cell death• The dose dependence of 
toxicity was determined at 72 h. Mixed cultures of neurons 
and  astrocytes were treated  with  camptothecin for 72 h, 
and neuronal survival was determined using CFDA assay• 
Parallel cultures of confluent astrocytes were treated with 
camptothecin, and astrocyte survival was determined at 72 h 
using the MTT viability assay. Camptothecin treatment re- 
suited in cell death with 1(250 values of 0.44 and 6.9 ixM for 
neurons  and  astrocytes,  respectively  (Fig.  2  A).  The  16- 
fold  difference  in  the  1(250 values  for  camptothecin- 
induced toxicity of neurons and astrocytes demonstrated 
that astrocytes were more resistant,  confirming the  mor- 
phological observations. 
The time course of cellular toxicity was similarly deter- 
mined using both mixed cultures of neurons and astrocytes 
and purified cultures of astrocytes. Cultures were treated 
with 10 p~M camptothecin, and neuronal and astrocyte sur- 
vival  was  determined  at  0,  24,  48,  and  72  h.  Neurons 
treated  with camptothecin died more rapidly than  astro- 
cytes (Fig. 2 B). After 24 h, neuronal survival was ~30% 
of control values, whereas no astrocyte cell death was ap- 
parent.  Astrocyte  toxicity  was  not  observed  until  48  h, 
where survival was ~-,83%  of control, untreated  cultures. 
At 72 h, virtually all neurons had died, while ~'-,63% of as- 
trocytes were still viable. 
Cell Death Is Independent of DNA Synthesis 
The  S-phase  specificity  of camptothecin  has  been  sup- 
ported by the fact that aphidicolin,  an inhibitor of DNA 
polymerase a, prevented camptothecin-induced cell death 
in cycling cells (13, 28)• To further confirm that DNA rep- 
lication does not contribute to camptothecin-induced neu- 
ronal death, mixed cultures of neurons and astrocytes were 
treated  with camptothecin in the presence and absence of 
increasing concentrations of aphidicolin, and neuronal sur- 
vival was determined  after 24 h  in vitro. Aphidicolin was 
unable  to  protect  neurons  from  camptothecin-induced 
neurotoxicity (Fig. 3), suggesting that DNA polymerase 
activity does not contribute to camptothecin-induced neu- 
ronal death.  In addition,  aphidicolin  treatment  itself did 
not produce any significant degree of neuronal death• 
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Figure 2.  Dose-response and 
time course of camptothecin- 
induced cell death. (.4) Dose- 
response  for  camptothecin- 
induced  cell  death.  Mixed 
cultures  were  treated  with 
various doses of camptothe- 
cin and cell survival was eval- 
uated at 72 h after initiating 
treatment. Neuron and astro- 
cyte survival were assayed by 
the CFDA and MT£ assays, 
respectively.  Data  are  ex- 
pressed as percent control of 
the mean +__ SD (n = 3--4 per 
condition).  The  effect  of 
I  '  I  '  I  I  camptothecin  on  both  neu- 
0  24  48  72  ron  and  astrocyte  survival 
was significant  (P  <  0.0001 
Hours ill v/tro  by  one-way  ANOVA).  (B) 
Time  course  of  toxicity  of 
neurons and astrocytes evaluated after 10 o~M camptothecin treatment. Neuron and astrocyte survival were assayed as described above. 
Data are expressed as percent control of the mean ±  SD (n = 4). The effects of camptothecin on neuron and astrocyte survival were 
significant  (P <  0.0001 by one-way ANOVA). O, astrocytes; I, neurons. 
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Figure 3.  Aphidicolin  does not prevent camptothecin-induced 
neuronal death. Mixed cultures were treated with 10 ixM camp- 
tothecin in the presence of increasing concentrations  of aphidi- 
colin (APC) and neuronal survival was assayed at 24 h by the 
CFDA assay. Data is expressed as mean ± SD (n = 3-4). 
Camptothecin Treatment Induces Neuronal Apoptosis 
Camptothecin treatment has been shown to induce apop- 
tosis in proliferating cells (4, 54). Apoptosis is character- 
ized by various morphological descriptions including con- 
densation of nuclear chromatin, shrinking of the cytoplasm, 
and blebbing of the membrane with formation of apop- 
totic bodies. To determine if camptothecin-induced neu- 
ronal death was apoptotic or necrotic, mixed cultures of 
neurons  and  astrocytes were  treated with  camptothecin 
and analyzed by continuous time lapse video microscopy. 
In parallel, other cultures were treated with a high concen- 
tration of rotenone (1  IxM), which inhibits complex-I of 
the mitochondrial electron transport chain and induces ne- 
crosis (25). In control cultures of 2% FCS alone, there was 
little change in neuronal survival at 24 h, although some 
neuronal  migration  was  evident  (Fig.  4  A).  Rotenone 
treatment induced a rapid cell death within 3 h which mor- 
phologically consisted of cell swelling and disintegration 
characteristic of necrosis (Fig. 4 B). Camptothecin-induced 
neuronal death had a slower onset and was accompanied 
by a dramatic change in neuronal morphology (Fig. 4 C). 
Neuronal death was characterized by somal zeiosis (plasma 
membrane  blebbing  and  contraction),  fragmentation  of 
neurites, and eventually cell body shrinkage leaving a phase- 
bright, cell "ghost." This morphology is characteristic of 
apoptosis and occurred over a period of 4-8 h. While most 
neurons died within 12-24 h, a few survived for longer times. 
Apoptotic cell death is  typically accompanied by con- 
densation of nuclear chromatin (70). DNA-intercalating 
dyes can be used to visualize condensed DNA, which usu- 
ally  appears  as  several  brightly-stained  DNA  "clumps" 
marginating  at  the  nuclear  envelope.  To  determine  if 
camptothecin could induce apoptotic chromatin condensa- 
tion in neurons, cells were treated with camptothecin (10 
~M) and the nuclei were visualized by staining with the 
nuclear dye DAPI after 18 h of incubation. Under control 
conditions,  neuronal  nuclei  appeared  smaller  and  more 
brightly stained than astrocytic nuclei (Fig. 5 A). In addi- 
tion,  the  nuclei  of both  cell types  appeared  round  and 
largely intact. After camptothecin treatment, many neu- 
rons had undergone nuclear chromatin condensation char- 
acteristic of apoptosis (Fig. 5 C, arrows), whereas astro- 
cytes were unaffected (Fig. 5 C, arrowhead). After 18 h of 
camptothecin treatment, 24.2 ___ 9.6% of the neurons had 
condensed  nuclear  chromatin,  as  compared  with  1.4  ___ 
0.1% of the neurons in control cultures. 
DNA  fragmentation is  considered the  hallmark  mor- 
phological feature of apoptosis and is characterized by the 
activation of a Ca2+/Mg2+-dependent endonuclease which 
cleaves DNA into 180--200 base pair oligonucleosomal size 
fragments which can be visualized by agarose gel electro- 
phoresis (69). Neuronal apoptosis is typically accompanied 
by DNA fragmentation in vitro and in vivo (15). In addi- 
tion, camptothecin treatment of cycling cells results in ap- 
optotic DNA fragmentation (19). Therefore, we wished to 
determine if camptothecin could induce apoptotic DNA 
fragmentation in neurons. Evaluation of DNA fragmenta- 
tion by agarose gel electrophoresis is impractical due to 
the presence of glial cells in our mixed cultures. Therefore, 
we utilized the TUNEL assay to specifically label and visu- 
alize  those  cells  that  contained  nuclei  with  fragmented 
DNA. This assay takes advantage of the large numbers of 
free 3'-OH DNA ends generated by endonuclease cleav- 
age, which can be labeled with digoxigenin-dUTP via the 
TdT  enzyme.  Camptothecin-induced  cleavable-complex 
formation, itself, has been reported not to induce TUNEL 
labeling, presumably because topo-I is covalently linked to 
the free 3'-OH DNA end (24). Few labeled cells were ob- 
served in untreated control cultures (Fig. 6 A). However, 
cultures that were treated with 10 IxM camptothecin for 18 h 
contained many labeled neurons (Fig. 6 B) characterized 
by darkly stained nuclei. Camptothecin treatment did not 
cause any labeling of astrocyte nuclei (Fig. 6 B). As a posi- 
tive control, cultures were treated with DNAse-I (1 txg/ml 
for 20 min) before TdT labeling. In these cultures, both 
neuron and  astrocyte nuclei labeled positively (data not 
shown). These data suggest that camptothecin treatment 
of neurons results  in  the  activation of an  endonuclease 
that induces apoptotic DNA fragmentation. 
ATA Inhibits Camptothecin-induced Neuronal Death 
Since  camptothecin  treatment  induced  apoptotic  DNA 
fragmentation  in  neurons,  we  wished  to  determine 
whether ATA, an inhibitor of the putative apoptotic endo- 
nuclease  (2),  could  prevent  camptothecin-induced  neu- 
ronal death. Neurons were therefore cotreated with ATA, 
up to 250 ~M in the presence of 10 IxM camptothecin for 
24 h in vitro. ATA partially protected neurons from camp- 
tothecin-induced toxicity (Fig.  7).  Treatment with  ATA 
(250 txM) alone had no effect on neuronal survival. These 
results  suggest  that  camptothecin  treatment  of neurons 
can  result  in  the  activation  of an  endonuclease  which 
cleaves neuronal DNA during apoptosis. 
Neuronal Death Is Mediated by DNA Topoisomerase-I 
To determine if camptothecin-induced neuronal death is 
specific to agents  which inhibit  topo-I, stereoisomers of 
The Journal of Cell Biology, Volume 134, 1996  762 Figure 4.  Camptothecin treatment of neurons results in morphological changes typical of apoptosis. Cortical neurons were grown for 
6-7 d in vitro on a preexisting monolayer of astrocytes in slide chamber flasks. Cells were recorded by phase-contrast, continuous time- 
lapse videomicroscopy under (A) control conditions, (B) 1 p~M rotenone treatment, or (C) 10 ~M camptothecin. Little neuronal death 
was observed within 24 h in control conditions (see arrow, A), whereby rotenone induced a rapid cell death consisting of cell swelling 
and disintegration characteristic of necrosis (see arrow, B). Camptothecin-induced neuronal death was characterized by a slower onset 
associated with cytoplasmic blebbing and contraction that lasted ~4-8 h and was characteristic of apoptosis (see arrow, C). 
the camptothecin analog, MDCPT, were used (Fig. 8). The 
20(S)-isomer  of MDCPT (S-MDCPT)  is active while  the 
20(R)-isomer of MDCPT (R-MDCPT) is inactive in trap- 
ping topo-I on DNA and causing strand breaks (45). In ad- 
dition,  the stereospecificity of MDCPT correlates  closely 
with  its antitumor  activity; S-MDCPT, which is more ac- 
tive  than  20(S)-camptothecin,  is  one  of the  most potent 
known  camptothecin  analogues  (50).  Treatment  of neu- 
rons  with  S-MDCPT  resulted  in  a  dose-dependent  cell 
death.  S-MDCPT was ~70  x  as potent  as 20(S)-campto- 
thecin in producing neural cell death  (Fig. 8) over a  24-h 
incubation period: the IC50 value for S-MDCPT was 0.081 
p~M as compared with  an IC50 value for camptothecin of 
5.5  IxM.  Treatment  with  the inactive isomer,  R-MDCPT, 
did not cause neuronal cell death. These data strongly sug- 
gest that camptothecin-induced neuronal death is specifi- 
cally mediated by inhibition of the target enzyme, topo-I. 
RNA and Protein Synthesis Inhibitors Prevent 
Camptothecin-induced Neuronal Death 
Neuronal apoptosis after trophic factor withdrawal can be 
Morris and Geller Camptothecin-induced  Neuronal  Apoptosis  763 Figure 5.  Camptothecin treatment of neurons results in apoptotic 
chromatin condensation. Cultures of neurons and astrocytes were 
treated without (A and B) or with (C and D) 10 ~M camptothe- 
cin for 18 h in vitro and stained with DAPI (A and C) and neu- 
rofilament antibody (B and D). Camptotheein treatment resulted 
in the condensation of nuclear chromatin in neurons (arrows, C). 
The chromatin condensation pattern  appeared as tight, compact 
clumps  typically  associated  with  cells undergoing  apoptosis. 
There was no significant induction of chromatin condensation in 
astrocytes (arrowhead, C) by camptotheein treatment. Bar, 20 lun. 
blocked with inhibitors of RNA and protein synthesis, sug- 
gesting that neuronal death depends upon the expression 
of a gene(s) involved in the apoptotic pathway (37). To de- 
termine  whether  camptothecin-induced  neuronal  death 
was also dependent upon active transcription or transla- 
tion, ActD and DRB, inhibitors of RNA synthesis, were 
added to cultures along with 10 ~M camptothecin. Neuron 
survival was  assayed  after  24  h.  ActD  can  inhibit  both 
rRNA and mRNA synthesis (48), while DRB is a specific, 
reversible inhibitor of RNA polymerase II and preferen- 
tially inhibits mRNA synthesis (8).  Both ActD and DRB 
inhibit the death of sympathetic neurons after NGF depri- 
vation  (37).  Neither  ActD  nor  DRB  were  toxic  when 
added alone at the maximum concentrations tested, sug- 
gesting that large-scale inhibition of transcription does not 
lead to neuronal cell death in our cultures. Both ActD and 
DRB protected neurons from camptothecin toxicity (Fig. 
9). This protection was dose dependent; modest protection 
was observed at the  lowest concentration of ActD used 
(0.005  ~g/ml) while total protection was achieved at con- 
centrations above 0.05 ~g/ml (Fig. 9 A). Significant protec- 
tion from toxicity was only observed at the highest concen- 
tration  of  DRB  used  (100  ~M),  which  offered  almost 
complete  inhibition  of camptothecin-induced cell  death 
(Fig. 9 B). The IC50 values for both ActD and DRB corre- 
late with their ability to effectively inhibit RNA synthesis 
(48),  suggesting that transcription is necessary for camp- 
tothecin-induced neuronal apoptosis. Since camptothecin 
has also been reported to inhibit RNA synthesis, we evalu- 
ated the ability of 10 ixM camptothecin, 100 ~M DRB, and 
Figure 6.  Camptothecin treatment  induces apoptotic DNA frag- 
mentation in neurons. Mixed cultures were treated with and with- 
out 10 I~M camptothecin for 18 h. Cultures were labeled with the 
TUNEL assay and differential interference contrast images were 
captured.  Untreated cultures (A) were not significantly labeled 
while camptothecin-treated  cultures (B) contained many labeled 
neurons with darkly stained nuclei. Camptothecin treatment  did 
not result in positive staining of astrocytes (B). Bar, 30 I~m. 
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Figure 7.  ATA inhibits camptothecin-induced  neuronal  death. 
Cultures were incubated with 10 I~M camptothecin in the pres- 
ence of increasing concentrations of ATA. Neuronal survival was 
determined  at 24 h by the  CFDA assay. Data is expressed  as 
mean  +- SD (n  =  3-4).  ATA significantly prevented  neuronal 
death  after  camptothecin  treatment  (P  <  0.0001 by one-way 
ANOVA). 
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Figure 8.  Camptothecin-induced  neuronal death is mediated by 
DNA  topoisomerase-I. Dose-response  curve  of neuronal  cell 
death evaluated after treatment with camptothecin or stereoiso- 
mers of the camptothecin analog, MDCPT. Neurons were treated 
with the above indicated agents and survival was evaluated by the 
CFDA assay at 24 h in vitro. Data are expressed as percent con- 
trol of the mean -  SD (n = 3--4). The effects of camptothecin and 
S-MDCPT on neuronal survival were significant (P <  0.0001 by 
one-way ANOVA), while the effects of R-MDCPT were not sig- 
nificant.  The  chemical  structures  for both 20(S)-camptothecin 
(CPT) and S-MDCPT are depicted. 
0.5  p,g/ml ActD to inhibit  transcription  in astrocyte and 
mixed cultures.  After 5 h  of incubation, these concentra- 
tions of DRB and ActD inhibited [3H]uridine incorpora- 
tion by 41  and 90%, respectively, while camptothecin in- 
hibited [3H]uridine incorporation by 39% (data not shown). 
Thus, the toxicity of camptothecin cannot be ascribed to 
an inhibition of RNA synthesis. 
To  investigate  if  camptothecin-induced  cell  death  is 
dependent upon new protein synthesis, neurons were co- 
treated with the protein synthesis inhibitors cycloheximide 
(CHX) and anisomycin (ANM).  Neither of these inhibi- 
tors, when used alone at the maximal concentration, were 
neurotoxic  within  the  24-h  treatment  period.  CHX was 
used in a range of concentrations from 5 ng/ml to 0.5  ~g/ 
ml, since similar concentrations of CHX have been shown 
to inhibit protein synthesis in sympathetic neurons (37). In 
addition, we found that 0.5  p,g/ml CHX inhibited cortical 
neuronal protein synthesis by ~50% after a 5-h treatment 
period;  maximal  inhibition  of  protein  synthesis  was 
achieved at 1 ~g/ml (data not shown). Significant protec- 
tion by CHX was only observed at the highest concentra- 
tion  used,  0.5  ~g/ml  (Fig.  10  A).  Similarly,  addition  of 
ANM prevented neuronal death by camptothecin (Fig. 10 
B); protection was observed at the  lowest concentration 
used, 0.5  txM. The surviving neurons in cultures cotreated 
with  camptothecin  and  protein  synthesis  inhibitors  ap- 
peared healthy and identical to neurons in control condi- 
tions and after treatment with CHX and ANM alone (data 
not shown).  These data suggest that protein synthesis is 
necessary for the  induction  of neuronal  death by camp- 
tothecin.  This  also  demonstrates  that  camptothecin  is 
probably not toxic to neurons by its ability to inhibit tran- 
scription, and thereby indirectly affecting protein synthesis. 
Camptothecin Sensitivity Is Correlated with Levels of 
Transcription and Topo-I Expression 
Topo-I is involved in both DNA replication and transcrip- 
tion. In other systems, the sensitivity to camptothecin has 
been correlated  with  levels of topo-I protein  expression 
(12). We therefore evaluated the levels of topo-I in neu- 
rons and astrocytes. Protein was isolated from E  17 rat ce- 
rebral cortex as well as from cortical neurons after 2 d in 
culture and confluent cultures of purified cerebral cortical 
astrocytes.  The  extracts  were  subjected  to  SDS-PAGE, 
transferred  to  nitrocellulose,  and  immunoblotted with  a 
polyclonal  antibody  to  human  topo-I which  also  recog- 
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Figure 9.  RNA synthesis  in- 
hibitors  prevent  camptothe- 
cin-induced  neuronal  death. 
Mixed  cultures  were treated 
with  10  p,M  camptothecin 
with  increasing  concentra- 
tions  of the  RNA  synthesis 
inhibitors,  (A) ActD or (B) 
DRB. Neuronal survival was 
evaluated  at  24  h  with  the 
CFDA  assay.  Data  are  ex- 
pressed as mean -+ SD (n  = 
3--4). The effects of ActD and 
DRB  on  neuronal  survival 
were significant  (P <  0.0001 
by one-way ANOVA). 
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Figure  10.  Protein  synthesis 
inhibitors  prevent camptoth- 
ecin-induced  neuronal  death. 
Mixed  cultures  were treated 
with  10  p~M  camptothecin 
with  increasing  concentra- 
tions of the protein synthesis 
inhibitors,  (A)  CHX or  (B) 
ANM. Neuronal survival was 
evaluated  at  24  h  with  the 
CFDA  assay.  Data  are  ex- 
pressed as mean -+ SD (n  = 
3-4). The effects of CHX and 
ANM  on  neuronal  survival 
were significant (P <  0.0001 
by one-way ANOVA). 
nizes  the  rat  100-kD  topo-I.  The  immunoblots  demon- 
strate that topo-I levels are significantly higher in embry- 
onic brain  and cultures  of neurons  than in  the  astrocyte 
cultures, although astrocytes did express a small amount of 
topo-I  (Fig.  11).  When  the  pixel intensity  of the  bands 
were analyzed, cultured neurons and neurons from embry- 
onic brain expressed ~2.3- and 4.4-fold higher topo-I lev- 
els  than  astrocytes, respectively. These data  suggest that 
neurons  might  be  more  sensitive  to  camptothecin  com- 
pared to astrocytes due to differences in topo-I expression. 
Given that  the  degree of cell division in  our astrocyte 
cultures  is low, the  primary function  of topo-I would  be 
most likely to  relieve stress in  DNA generated  by tran- 
scription. We therefore evaluated levels of transcriptional 
activity of neurons in mixed cultures as compared with the 
level in purified astrocyte cultures by measuring [3H]uri- 
dine incorporation over time. Neurons incorporated ~5.5 
×  the amount of [3H]uridine on a per unit protein basis as 
compared  with  astrocytes  (data  not  shown).  Taken  to- 
gether  with the  data  on  the  prevention  of cell death  by 
transcriptional inhibition,  the differences in sensitivity of 
neurons and astrocytes to camptothecin appears to be re- 
lated to their levels of transcription and topo-I expression. 
Discussion 
Our data demonstrate that camptothecin, a cell cycle-spe- 
cific anticancer agent, exhibited significant toxicity toward 
postmitotic  central  nervous  system  neurons  in  culture. 
Camptothecin-induced  neuronal  death  was accompanied 
by DNA fragmentation and chromatin condensation,  cell 
blebbing,  cytoplasmic  shrinkage,  and  fragmentation  of 
neurites,  all  characteristics  of  neuronal  apoptotic  cell 
death.  Furthermore,  neuronal  death  was  inhibited  by 
drugs which prevent RNA and protein synthesis, suggest- 
ing that the camptothecin-induced  death  of neurons was 
dependent  upon active transcription and translation.  As- 
trocytes were less sensitive to camptothecin, even though 
some of the astrocytes in these cultures were proliferating. 
Astrocytes expressed less  topo-I protein  compared with 
cultured neurons and embryonic brain suggesting that the 
level of topo-I expression might be an important determi- 
nant in the sensitivity of neural cells to topo-I inhibitors. In 
addition,  astrocytes  incorporated  less  [3H]uridine  than 
neurons,  suggesting  that  the  degree  of  RNA  synthesis 
might also contribute to camptothecin sensitivity. With the 
use  of stereospecific topo-I inhibitors,  we  demonstrated 
that neuronal death is a direct result of inhibition of topo-I, 
suggesting that the function of this enzyme is essential for 
neuronal survival. 
Camptothecin Causes Neuronal Apoptosis 
Camptothecin induces an apoptotic death in many differ- 
ent  cell  types, and  our  data  clearly demonstrate  that  it 
does so in nondividing neurons.  Within 24 h  after camp- 
tothecin treatment, neurons  undergo  the  same apoptotic 
morphological  changes  which  occur  after  trophic  factor 
deprivation (15): the plasma membrane begins to undergo 
dramatic blebbing and contraction (zeiosis) and the neu- 
rites begin to disintegrate. This is followed by cytoplasmic 
shrinkage, which eventually leaves a  small, round, phase- 
bright, cell ghost. In addition, camptothecin-treated neu- 
rons undergo chromatin condensation and DNA fragmen- 
tation.  At  the  highest  concentrations  used,  inhibitors  of 
RNA and protein synthesis fully protect against campto- 
thecin toxicity. Protection by these agents is typically ob- 
served in neuronal apoptosis (37). Apoptosis was also re- 
Figure 11.  Immunoblot of topo-I protein in neural tissues. Ex- 
tracts of E 17 rat cerebral cortex (B), E 17 neurons after 2 days in 
culture (iV), and purified cultures of newborn rat cerebral cortical 
astrocytes (A) were subjected to SDS-PAGE electrophoresis  and 
transferred to nitrocellulose. Topo-I immunoreactivity to an anti- 
human rabbit polyclonal antibody was visualized as a single 100-kD 
band. 
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ATA normally fully protects many neurons from apopto- 
sis  (2), it offered only partial protection against campto- 
thecin-induced cell death. It is possible that more than one 
endonuclease which is less sensitive to inhibition by ATA, 
might be active during the apoptotic process. In addition, 
our studies were performed with rat cerebral cortical neu- 
rons, which may differ from other neurons in their sensi- 
tivity to  endonuclease inhibition.  Taken  together, these 
data demonstrate that the topo-I inhibitor, camptothecin, 
can induce apoptosis in neurons. 
Camptothecin Toxicity Is Mediated by Topoisomerase-I 
Topo-I is the only known target of camptothecin (21). The 
involvement of topo-I in camptothecin-induced neurotox- 
icity was established by the use of stereospecific isomers of 
the camptothecin analogue, MDCPT. Topo-I is an enzyme 
used in the relaxation of DNA supercoiling during replica- 
tion and transcription (for review see 65). Topo-I catalyzes 
the "breakage-reunion" reaction of DNA, resulting in the 
separation and rejoining of one DNA strand. This activity 
allows  the  DNA  to  "swivel" in  response  to  a  torsional 
stress generated by the movement of the replication and/ 
or transcription machinery along the DNA double-helix. 
Camptothecin does not bind to topo-I or DNA alone but 
binds to a topo-I/DNA complex and traps topo-I in an in- 
termediate state, thereby effectively inhibiting the rejoin- 
ing step of the breakage-reunion reaction. This results in 
the formation of a drug/topo-I/DNA complex (the cleav- 
able complex) (27) with topo-I covalently attached to the 
3'-OH end of the severed DNA backbone, thus creating a 
DNA single-strand break. It is the collision of the DNA 
replicational machinery with the cleavable-complex that is 
thought to generate potentially lethal DNA double-strand 
breaks (28). This is supported by the fact that aphidicolin, 
an inhibitor of replicative DNA polymerase et, abolishes 
camptothecin-induced toxicity in proliferating cells (28). 
In  our experiments, aphidicolin offered no protection 
against  camptothecin  toxicity,  a  not  unexpected  result, 
since quiescent neurons do not express DNA polymerase 
(66). Thus, there must be alternative mechanisms, inde- 
pendent of DNA synthesis, by which inhibition of topo-I 
can produce cell death. We propose that DNA damage oc- 
curs by the collision of the transcriptional machinery with 
the cleavable-complex, an event analogous to camptothe- 
cin-mediated, replicationally driven DNA strand breaks. 
In  vitro transcription  assays  demonstrate  that  the  tran- 
scriptional machinery can indeed collide with the cleav- 
able-complex, on the DNA template strand,  resulting in 
the premature termination of transcription (3). Moreover, 
topo-I is preferentially found at transcriptionally active re- 
gions of DNA (65) and can be found in significant quanti- 
ties in the nucleolus (41), the primary site for transcription 
of rRNA in the cell. Treatment of cells with high concen- 
trations of camptothecin results in transcriptional inhibi- 
tion of mainly large rRNA and mRNA transcripts (31, 71). 
While  some  transcriptional  inhibition  by  camptothecin 
takes place in our experiments, this is unlikely to contrib- 
ute to toxicity, since the other transcriptional inhibitors, 
both more effective at inhibition of RNA synthesis, were 
without toxicity when used by themselves. In addition, if 
camptothecin-induced neuronal death were due to general 
transcriptional inhibition, cotreatment with ActD or DRB 
should result in additive toxicity. Our data, which demon- 
strate that camptothecin neurotoxicity was reduced by ei- 
ther ActD or DRB, suggest that cell death could be due to 
DNA damage caused during the transcriptional process. 
Sensitivity to camptothecin could also be due to the lack 
of efficacy of DNA  repair. The repair of camptothecin- 
induced damage to cells depends upon functional repair 
mechanisms (26). Yeast cells with a deletion of the RAD52 
DNA repair gene are hypersensitive to camptothecin and 
cannot  repair  DNA  double-strand  breaks  formed  after 
camptothecin treatment (44). Moreover, cell lines that are 
deficient in  the  DNA  repair  enzyme poly(ADP-ribose) 
polymerase are hypersensitive to camptothecin (6), as are 
cells derived from individuals with the inherited disease 
Cockayne Syndrome (CS) (55), a defect in transcription- 
coupled DNA repair. CS cells are also hypersensitive to 
UV and ionizing radiation-induced DNA damage (34, 61). 
Interestingly, patients with CS are typically born with se- 
vere neurological abnormalities characterized by massive 
neuronal and glial cell death, demyelination, and the pres- 
ence of Alzheimer's-like neurofibrillary tangles (53). There- 
fore, neurons may be relatively deficient in DNA repair 
and consequently sensitive to DNA damage produced by 
topo-I inhibitors. 
Astrocytes Are Less Sensitive to Camptothecin 
Astrocytes were consistently less sensitive than neurons to 
toxic actions of camptothecin. This seems counterintuitive, 
since astrocytes are not terminally differentiated and pro- 
liferate at a low rate in our cultures. Differences in rates of 
transcription might explain this difference in sensitivity to 
camptothecin. Our data indicate that the rate of incorpo- 
ration of [3H]uridine was ~5.5 times greater into cultured 
rat cortical neurons than astrocytes, consistent with previ- 
ous data showing that neurons have two to three times the 
transcriptional activity of glial cells (22). In addition, use 
of cell-free transcriptional assays demonstrated that neu- 
rons also have double the number of available RNA tran- 
scriptional initiation sites on chromatin compared to glial 
cells (52). The fact that neurons had significantly higher 
levels  of topo-I  than  astrocytes might  also  explain  the 
greater sensitivity of neurons  to  camptothecin.  Overex- 
pression of topo-I in yeast (21) and BHK cells (36) leads to 
camptothecin hypersensitivity, suggesting that the neurons 
are more sensitive to camptothecin because they express 
higher levels of topo-I. Another possibility is  that there 
may be differences in topo-I activity via posttranslational 
modification. Topo-I activity can be modulated by both 
phosphorylation  and  ADP  ribosylation  of  the  enzyme 
(29). However, the mechanisms by which topo-I activity is 
regulated in neurons and astrocytes are not known. 
Another explanation for the different camptothecin sen- 
sitivities might be that  astrocytes differ from neurons in 
their apoptotic pathway. Astrocytes are particularly resis- 
tant to other conditions which produce apoptosis in neu- 
rons, such as ionizing radiation (8a), oxidative stress (20), 
and staurosporine treatment (32), suggesting that impor- 
tant differences between these cell types might be in the 
apoptotic machinery itself. For example, expression of the 
Morris and Geller Camptothecin-induced Neuronal Apoptosis  767 apoptosis-inhibiting  proto-oncogene, bcl-2, is  higher  in 
cultured mouse astrocytes than neurons (38), and constitu- 
tive expression of bcl-2 reduces camptothecin-induced apop- 
tosis in cycling cells (64a). Therefore, neurons and astro- 
cytes may express different inducers and suppressors of 
apoptosis which ultimately modulate topo-I-mediated cell 
death. Finally, astrocytes repair DNA damage from ioniz- 
ing radiation faster than neurons (8a), suggesting that dif- 
ferences in DNA repair might mediate camptothecin sen- 
sitivity in these cell types. Understanding why these cells 
differ in their sensitivity to camptothecin could have broad 
implications for the understanding of apoptosis related to 
cancer and neuronal development as well as topo-I func- 
tion in the CNS. 
Summary 
Our results demonstrate that camptothecin is toxic to ter- 
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Figure 12.  Proposed model for camptothecin-induced  neuronal 
apoptosis. Camptothecin binds and inactivates topo-I forming the 
cleavable-complex. Collision of the transcription machinery with 
the cleavable-complex causes DNA damage, which leads to apop- 
tosis if not repaired. The rate and competency of neuronal DNA 
repair would serve ultimately to determine the sensitivity of neu- 
rons to camptothecin. If unrepaired, DNA damage is then recog- 
nized by proteins such as the tumor suppressor p53, which then 
activate the apoptotic pathway and initiate the synthesis of pro- 
teins which cause cell death. Under this model, inhibition of tran- 
scription can block either DNA damage or expression of proteins 
involved in apoptosis. Protein synthesis inhibitors act similarly by 
blocking the expression of apoptotic factors. Finally, expression 
or activity of an apoptotic endonuclease(s)  is increased,  which 
causes neuronal DNA fragmentation  and can be inhibited  by 
ATA. 
minally differentiated cells that do not progress through 
S-phase.  Although  the  majority of evidence supports  a 
role for camptothecin toxicity mediated in the S-phase, ac- 
counts of non-S-phase killing by camptothecin have been 
reported (5, 11). In addition, treatment of a variety of hu- 
man  cell lines  with  camptothecin resulted in  cell death 
which did not correlate with cell cycle kinetics (47). Our 
data suggest that toxicity to nondividing cells is correlated 
with the level of active RNA transcription. We propose a 
model to illustrate  the process of camptothecin-induced 
apoptotic death in postmitotic neurons (Fig.  12).  In this 
model, the initial process is the binding of camptothecin to 
topoisomerase-I and DNA to form the cleavable-complex; 
this inactivation of topo-I then results in the formation of 
DNA  strand  breaks  during  the  transcriptional  process. 
While the signal transduction pathways involved have not 
yet been elucidated, we posit a role for tumor suppressor 
proteinp53  in initiating the apoptotic process. Camptothe- 
cin induces p53 expression (58) and p53 is required for ap- 
optosis following DNA damage by radiation or anticancer 
agents (35); p53 expression in neurons is increased after 
DNA  damage  (68).  Downstream  events would  then  in- 
clude the synthesis of proteins involved in the apoptotic 
process,  which  can  be  inhibited  by  inhibitors  of either 
RNA or protein synthesis. Finally, the cleavage of DNA is 
through the activation of an apoptotic endonuclease, the 
activity of which is inhibited by ATA. The major feature 
of this model is that DNA damage to neurons is during the 
transcriptional process. However, since inhibition of tran- 
scription would be expected to inhibit both DNA damage 
and the synthesis of genes involved in the apoptotic pro- 
gram, additional experiments to address the signal trans- 
duction pathways in camptothecin-mediated apoptosis will 
be necessary. Since these signal transduction pathways in- 
volve genes which also participate in the regulation of the 
cell cycle, the use of terminally differentiated neurons for 
these studies will permit the detailed molecular analysis of 
the apoptotic events uncluttered by the presence of a func- 
tioning cell cycle. 
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